Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.

Silje Watterdal SyversenIngrid JyssumAnne Therese TveterTrung T TranJoseph SextonSella Aarrestad ProvanSiri MjaalandDavid J WarrenTore K KvienGunnveig GrødelandLise S H Nissen-MeyerPetr RicanekAdity ChopraAne Marie AndersonGrete B KroJørgen JahnsenLudvig A MuntheEspen A HaavardsholmJohn T VaageFridtjof Lund-JohansenKristin Kaasen Jørgensen Guro Løvik Goll

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2022)

IMID patients had an attenuated response to the standard vaccination regimen as compared to healthy controls. A third vaccine dose was safe and resulted in serologic response in most patients. These data facilitate identification of patient groups at risk of an attenuated vaccine response, and they support administering a third vaccine dose to IMID patients with a weak serologic response to the standard regimen.

Keyphrases

end stage renal disease
sars cov
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
stem cells
mesenchymal stem cells
patient reported outcomes
case report
respiratory syndrome coronavirus
artificial intelligence
patient reported
data analysis
bioinformatics analysis